LONA · LeonaBio, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Based upon the Company's current operating plan, it estimates that its $51.1 million of cash, cash equivalents and investments at June 30, 2026 may not be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months which raises substantial doubt as to our ability to continue as a going concern following the date of this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 14, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-23 | JOHNSON JAMES A |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. |
Stock Option (Right to Buy)
|
28,000 |
| 2026-06-23 | PERCEPTIVE ADVISORS LLC |
10% Owner |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Indirect)
The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. Joseph Edelman ("Mr. Edelman") is the managing member of Perceptive Advisors LLC (the "Advisor"). The Advisor serves as the investment manager of Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). The Advisor may be deemed to have an indirect pecuniary interest in the securities reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Edelman's board service through a partial management fee offset. Each of the Master Fund and the Advisor disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that either the Master Fund or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
Stock Option (Right to Buy)
(I)
|
28,000 |
| 2026-06-23 | PICKERING GRANT |
Director, CHIEF EXECUTIVE OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. |
Stock Option (Right to Buy)
|
28,000 |
| 2026-06-23 | EDELMAN JOSEPH |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. |
Stock Option (Right to Buy)
|
28,000 |
| 2026-06-23 | Kosacz Barbara |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. |
Stock Option (Right to Buy)
|
28,000 |
| 2026-06-23 | Panzara Michael A. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. |
Stock Option (Right to Buy)
|
28,000 |
| 2026-06-23 | Romano Kelly A |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. |
Stock Option (Right to Buy)
|
28,000 |
| 2026-06-23 | Silverman Peter B. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy and is pro-rated based on the reporting person's appointment to the Issuer's board of directors on May 5, 2026. |
Stock Option (Right to Buy)
|
2,333 |
| 2026-06-23 | Holles Natalie C. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy and is pro-rated based on the reporting person's appointment to the Issuer's board of directors on May 5, 2026. |
Stock Option (Right to Buy)
|
2,333 |
| 2026-06-23 | Callori Fred |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy and is pro-rated based on the reporting person's appointment to the Issuer's board of directors on May 5, 2026. |
Stock Option (Right to Buy)
|
2,333 |
| 2026-05-05 | Silverman Peter B. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option are scheduled to vest monthly over a term of 36 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Stock Option (Right to Buy)
|
56,000 |
| 2026-05-05 | Callori Fred |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option are scheduled to vest monthly over a term of 36 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Stock Option (Right to Buy)
|
56,000 |
| 2026-05-05 | Holles Natalie C. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option are scheduled to vest monthly over a term of 36 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Stock Option (Right to Buy)
|
56,000 |
| 2026-04-09 | Litton Mark James |
Director, PRESIDENT and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Stock Option (Right to Buy)
|
750,000 |
| 2026-04-09 | PERCEPTIVE ADVISORS LLC |
10% Owner |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Indirect)
The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. Joseph Edelman ("Mr. Edelman") is the managing member of Perceptive Advisors LLC (the "Advisor"). The Advisor serves as the investment manager of Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). The Advisor may be deemed to have an indirect pecuniary interest in the securities reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Edelman's board service through a partial management fee offset. Each of the Master Fund and the Advisor disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that either the Master Fund or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
Stock Option (Right to Buy)
(I)
|
28,000 |
| 2026-04-09 | San Martin Javier |
CHIEF MEDICAL OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Stock Option (Right to Buy)
|
350,000 |
| 2026-04-09 | EDELMAN JOSEPH |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Stock Option (Right to Buy)
|
28,000 |
| 2026-04-09 | JOHNSON JAMES A |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Stock Option (Right to Buy)
|
28,000 |
| 2026-04-09 | FLUKE JOHN M JR |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Stock Option (Right to Buy)
|
28,000 |
| 2026-04-09 | CHURCH KEVIN |
CHIEF SCIENTIFIC OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Stock Option (Right to Buy)
|
300,000 |
| 2026-04-09 | Kosacz Barbara |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Stock Option (Right to Buy)
|
28,000 |
| 2026-04-09 | Panzara Michael A. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Stock Option (Right to Buy)
|
28,000 |
| 2026-04-09 | Worthington Mark |
GENERAL COUNSEL and CCO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Stock Option (Right to Buy)
|
300,000 |
| 2026-04-09 | Renninger Robert |
CHIEF FINANCIAL OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Stock Option (Right to Buy)
|
300,000 |
| 2026-04-09 | PICKERING GRANT |
Director, CHIEF EXECUTIVE OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Stock Option (Right to Buy)
|
28,000 |
| 2026-04-09 | Romano Kelly A |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Stock Option (Right to Buy)
|
28,000 |
| 2026-03-04 | Litton Mark James |
Director, PRESIDENT and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the Issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock
|
5,156 |
| 2026-03-04 | San Martin Javier |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the Issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock
|
1,720 |
| 2026-03-04 | Worthington Mark |
GENERAL COUNSEL and CCO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the Issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock
|
1,328 |
| 2026-03-04 | CHURCH KEVIN |
CHIEF SCIENTIFIC OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the Issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock
|
1,359 |
| 2026-03-04 | Renninger Robert |
CHIEF FINANCIAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the Issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock
|
906 |
| 2026-03-03 | Renninger Robert |
CHIEF FINANCIAL OFFICER |
Convert↑
|
Common Stock
|
3,900 |
| 2026-03-03 | San Martin Javier |
CHIEF MEDICAL OFFICER |
Convert↑
|
Common Stock
|
7,418 |
| 2026-03-03 | CHURCH KEVIN |
CHIEF SCIENTIFIC OFFICER |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. On March 3, 2025, the reporting person was granted 5,856 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date. |
Restricted Stock Units
|
5,856 |
| 2026-03-03 | Worthington Mark |
GENERAL COUNSEL and CCO |
Convert↑
|
Common Stock
|
5,726 |
| 2026-03-03 | Litton Mark James |
Director, PRESIDENT and CEO |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. On March 3, 2025, the reporting person was granted 22,254 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date. |
Restricted Stock Units
|
22,254 |
| 2026-03-03 | San Martin Javier |
CHIEF MEDICAL OFFICER |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. On March 3, 2025, the reporting person was granted 7,418 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date. |
Restricted Stock Units
|
7,418 |
| 2026-03-03 | Worthington Mark |
GENERAL COUNSEL and CCO |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. On March 3, 2025, the reporting person was granted 5,726 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date. |
Restricted Stock Units
|
5,726 |
| 2026-03-03 | Litton Mark James |
Director, PRESIDENT and CEO |
Convert↑
|
Common Stock
|
22,254 |
| 2026-03-03 | CHURCH KEVIN |
CHIEF SCIENTIFIC OFFICER |
Convert↑
|
Common Stock
|
5,856 |
| 2026-03-03 | Renninger Robert |
CHIEF FINANCIAL OFFICER |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. On March 3, 2025, the reporting person was granted 3,900 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date. |
Restricted Stock Units
|
3,900 |
| 2026-01-02 | Renninger Robert |
CHIEF FINANCIAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person and the shares of common stock received upon settlement of the RSUs are subject to a lock-up agreement with Cantor Fitzgerald & Co. entered into in connection with the Issuer's private placement in December 2025. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $6.60 to $7.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock
|
297 |
| 2026-01-02 | CHURCH KEVIN |
CHIEF SCIENTIFIC OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person and the shares of common stock received upon settlement of the RSUs are subject to a lock-up agreement with Cantor Fitzgerald & Co. entered into in connection with the Issuer's private placement in December 2025. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $6.60 to $7.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock
|
876 |
| 2026-01-02 | Litton Mark James |
Director, PRESIDENT and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person and the shares of common stock received upon settlement of the RSUs are subject to a lock-up agreement with Cantor Fitzgerald & Co. entered into in connection with the Issuer's private placement in December 2025. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $6.60 to $7.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock
|
2,586 |
| 2026-01-02 | San Martin Javier |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person and the shares of common stock received upon settlement of the RSUs are subject to a lock-up agreement with Cantor Fitzgerald & Co. entered into in connection with the Issuer's private placement in December 2025. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $6.60 to $7.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock
|
1,644 |
| 2026-01-02 | Worthington Mark |
GENERAL COUNSEL and CCO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person and the shares of Common Stock received upon settlement of the RSUs are subject to a lock-up agreement with Cantor Fitzgerald & Co. entered into in connection with the Issuer's private placement in December 2025. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $6.60 to $7.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock
|
876 |
| 2025-12-31 | CHURCH KEVIN |
CHIEF SCIENTIFIC OFFICER |
Convert↑
|
Common Stock
|
3,667 |
| 2025-12-31 | CHURCH KEVIN |
CHIEF SCIENTIFIC OFFICER |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
RSUs convert into common stock on a one-for-one basis. Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. On October 1, 2024, the reporting person was granted 11,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. |
Restricted Stock Units
|
3,667 |
| 2025-12-31 | Litton Mark James |
Director, PRESIDENT and CEO |
Convert↑
Filing footnotes — Common Stock (Direct)
The reported number of shares in this Form 4 has been adjusted to reflect the impact of the Issuer's 10-for-1 reverse stock split completed on September 17, 2025 (the "Reverse Stock Split"). |
Common Stock
|
10,834 |
| 2025-12-31 | Renninger Robert |
CHIEF FINANCIAL OFFICER |
Convert↑
|
Common Stock
|
1,236 |